CJC-1295 No DAC

1. What is it?

No DAC means the absence of the additional component that allows original CJC-1295 to bind albumin in the blood. What remains is a modified 29-amino-acid peptide related to natural GHRH. The name MOD-GRF 1-29 is also used. The FDA described inconsistent use of these names and confusion between forms. The suffix should therefore not be treated as a cosmetic detail, and products should not be assumed identical on the basis of their names alone. [86] [87]

2. Why do people turn to it?

Proposed uses generally reflect expectations that stimulating the body's own GH will improve body composition or recovery. The materials found do not show that No DAC specifically achieves those goals in well-designed patient studies. Nor can it inherit the indications of the former Geref medicine, which contained sermorelin. A shared connection to GHRH does not establish identical action, treatment eligibility or effectiveness. [86] [65]

3. How does it work?

The molecule is intended to mimic the GHRH signal reaching the pituitary gland. Changes at several points in the chain distinguish it from the unmodified fragment of this hormone. The absence of DAC means that this particular way of prolonging activity through binding to albumin is absent. This does not allow us to calculate a reliable duration of action in humans or plan its use. Direct measurements of absorption, concentration and hormonal response would be needed for the precisely identified variant without DAC. [86] [85]

4. What do studies actually show?

In a 2010 paper, a laboratory analysed an unknown preparation from police and customs authorities. It identified a 29-amino-acid peptide consistent with the molecule sold as CJC-1295. FDA cited the publication in the non-DAC version's history. This examined a sample, without treating participants. It shows the structure can be identified, not whether the product improves health, how long it acts or which complications it causes. [87] [86]

5. What do we still not know?

The most common mistake is to cite the 2006 CJC-1295 studies as evidence for No DAC. The long-lasting effect in those studies was associated with the albumin-binding version. Results from older experiments on GRF analogues with single modifications also do not automatically describe today's molecule with four modifications. When assessing a source, establish the full structure and then check whether it studied humans and outcomes that matter to them, or only hormones or animals. [85] [89] [86]

6. What are the risks?

The FDA found no clinical safety data for the assessed free form of CJC-1295 without DAC or its acetate. This is a gap in knowledge, not proof that there are no side effects. The regulator also highlighted possible immune reactions associated with peptide aggregates and impurities. The documentation describes problems identifying the substance's form unambiguously. If a product's exact contents are unknown, even comparing its risks with a published study becomes unreliable. [86]

In sport governed by WADA rules, this form belongs to the prohibited group of GHRH-mimicking substances. Although No DAC and MOD-GRF are not listed separately in the 2026 list, the ban covers the entire group. It also applies outside competition. [108] [86]

7. Is it an approved medicine?

Review of CJC-1295 without DAC by a US compounding advisory committee does not mean approval of a medicine. FDA documentation assessed forms with DAC, without DAC and their salts separately, identifying different gaps in information. This assessment must not be reduced to a claim that the entire family was approved. It is not a Polish treatment indication either. This profile describes an experimental substance and the state of the evidence, not an approved therapy with proven benefits. [86]

8. What is new in research?

By 3 November 2026, no new primary study had been found that filled the main gap: assessing the benefits and safety of precisely identified No DAC in humans. A new October 2026 paper about CJC-1295 concerns detection of the DAC form in horses, so it does not change this assessment. Future updates to this profile will depend on data for the version without DAC itself, rather than another repetition of findings about a different molecule. [86] [88]

Where does this information come from?

References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.